ATE124726T1 - Wachstumsregelfaktoren für neuriten. - Google Patents

Wachstumsregelfaktoren für neuriten.

Info

Publication number
ATE124726T1
ATE124726T1 AT89912786T AT89912786T ATE124726T1 AT E124726 T1 ATE124726 T1 AT E124726T1 AT 89912786 T AT89912786 T AT 89912786T AT 89912786 T AT89912786 T AT 89912786T AT E124726 T1 ATE124726 T1 AT E124726T1
Authority
AT
Austria
Prior art keywords
proteins
metalloproteases
present
neurites
inhibitors
Prior art date
Application number
AT89912786T
Other languages
English (en)
Inventor
Martin E Schwab
Pierenrico W Caroni
Paolo A Paganetti
Original Assignee
Zuerich Erziehungsdirektion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/401,212 external-priority patent/US5684133A/en
Application filed by Zuerich Erziehungsdirektion filed Critical Zuerich Erziehungsdirektion
Application granted granted Critical
Publication of ATE124726T1 publication Critical patent/ATE124726T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/06—Chelate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
AT89912786T 1988-11-04 1989-11-02 Wachstumsregelfaktoren für neuriten. ATE124726T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26794188A 1988-11-04 1988-11-04
US07/401,212 US5684133A (en) 1988-11-04 1989-08-30 Neurite growth regulatory factors, antibodies thereto, and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE124726T1 true ATE124726T1 (de) 1995-07-15

Family

ID=26952762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89912786T ATE124726T1 (de) 1988-11-04 1989-11-02 Wachstumsregelfaktoren für neuriten.

Country Status (8)

Country Link
US (2) US6025333A (de)
EP (1) EP0396719B1 (de)
KR (1) KR100196540B1 (de)
AT (1) ATE124726T1 (de)
AU (2) AU652537B2 (de)
DE (1) DE68923362T2 (de)
DK (1) DK160190A (de)
WO (1) WO1990005191A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE124726T1 (de) * 1988-11-04 1995-07-15 Zuerich Erziehungsdirektion Wachstumsregelfaktoren für neuriten.
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
WO1993000427A2 (en) * 1991-06-24 1993-01-07 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
DK0610254T3 (da) * 1991-09-20 2005-01-10 Amgen Inc Glial-afledt neurotrofisk faktor
CA2117889A1 (en) * 1993-02-11 1994-08-18 Martin E. Schwab A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
WO1996032959A1 (en) * 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
AU7655596A (en) 1995-12-06 1997-06-27 Sumitomo Pharmaceuticals Company, Limited Novel semaphorin z and gene encoding the same
JP4108755B2 (ja) 1996-09-11 2008-06-25 大日本住友製薬株式会社 新規セマフォリン遺伝子：セマフォリンｙ
EP0945505A4 (de) 1996-10-09 2002-11-27 Sumitomo Pharma Neues semaphorin-gen: semaphorin w
WO1998022504A1 (en) 1996-11-15 1998-05-28 Sumitomo Pharmaceuticals Company, Limited Novel semaphorin genes (i)
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
SK287323B6 (sk) 1998-11-06 2010-07-07 University Of Z�Rich Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
YU53502A (sh) 2000-01-12 2005-11-28 Yale University Blokada aksonalnog rasta posredstvom nogo receptora
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
PT1325130E (pt) * 2000-10-06 2010-05-31 Biogen Idec Inc Homólogos do receptor de nogo
CN101035803A (zh) * 2004-10-01 2007-09-12 耶鲁大学 Nogo－a多肽片段、变异nogo受体－1多肽、及其应用
CA2594919A1 (en) * 2005-01-24 2006-08-03 Alnylam Pharmaceuticals, Inc. Rnai modulation of the nogo-l or nogo-r gene and uses thereof
EP1904091A4 (de) * 2005-07-07 2009-12-23 Univ Yale Zusammensetzungen und verfahren zur unterdrückung der axonalen wachstumshemmung
EP1909850A4 (de) 2005-07-21 2010-05-12 Alnylam Pharmaceuticals Inc Rnai-modulation des rho-a-gens und dessen verwendungen
CN101248083A (zh) * 2005-08-25 2008-08-20 比奥根艾迪克Ma公司 Nogo受体多肽和多肽片段及其用途
KR100756423B1 (ko) 2005-10-27 2007-09-07 한국과학기술연구원 성선자극호르몬 수용체를 바이오마커로 이용한 마이엘린의탐색방법
AU2006314528A1 (en) 2005-11-16 2007-05-24 Novartis Ag Biomarkers for anti-nogo-A antibody treatment in spinal cord injury
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
CA2670368C (en) * 2006-11-21 2018-05-29 Abbott Laboratories Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof
USD1082758S1 (en) * 2023-05-19 2025-07-08 DP Audio Video LLC Karaoke microphone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287184A (en) * 1977-11-23 1981-09-01 The Massachusetts General Hospital Process for healing wounds
US4407744A (en) * 1977-11-23 1983-10-04 Young David M Process for obtaining nerve growth factor
US4230691A (en) * 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
CA1173823A (en) * 1980-08-26 1984-09-04 Leonard M. Hjelmeland Nondenaturing zwitterionic detergent for membrane biochemistry
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
EP0155433A1 (de) * 1984-03-23 1985-09-25 Adriano Fontana Immunsuppressionsfaktor
CA1341401C (en) * 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
US4803163A (en) * 1984-06-04 1989-02-07 E. I. Du Pont De Nemours And Company Preparation of a protein fraction exhibiting cell growth-inhibiting activity
EP0233838A3 (de) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neuriten stimulierender Faktor und Prozess für seine Herstellung
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
ATE124726T1 (de) * 1988-11-04 1995-07-15 Zuerich Erziehungsdirektion Wachstumsregelfaktoren für neuriten.

Also Published As

Publication number Publication date
AU4528089A (en) 1990-05-28
DK160190D0 (da) 1990-07-03
WO1990005191A1 (en) 1990-05-17
US6025333A (en) 2000-02-15
KR900702050A (ko) 1990-12-05
KR100196540B1 (ko) 1999-06-15
EP0396719B1 (de) 1995-07-05
AU680932B2 (en) 1997-08-14
DK160190A (da) 1990-09-03
US6103232A (en) 2000-08-15
AU7435494A (en) 1994-12-15
DE68923362D1 (de) 1995-08-10
AU652537B2 (en) 1994-09-01
EP0396719A1 (de) 1990-11-14
DE68923362T2 (de) 1996-03-28

Similar Documents

Publication Publication Date Title
ATE124726T1 (de) Wachstumsregelfaktoren für neuriten.
HUT73799A (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
Mahaman et al. Involvement of calpain in the neuropathogenesis of Alzheimer’s disease
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
Peltonen et al. A defect in the structure of type I procollagen in a patient who had osteogenesis imperfecta: excess mannose in the COOH-terminal propeptide.
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
NO991951L (no) Tienopyrimidiner med fosfodiesterase V-inhiberende virkning
ATE301459T1 (de) Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
DE69703617D1 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
DK0755446T3 (da) Cardiotrophin og anvendelser deraf
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69633336D1 (de) Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
DE69923998D1 (de) Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
WO1993000427A3 (en) Neurite growth regulatory factors
ATE208196T1 (de) Verwendung von lemellarin alkaloiden in therapeutischen verfahren
DE60137414D1 (de) Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
GB9607249D0 (en) Compounds
DE3875065D1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
ATE391915T1 (de) Verwendung des proteins grf-1 zur auswahl von molekülen
WO2024040030A3 (en) Treating protein misfolding disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties